Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 3.59
- Piotroski Score 5.00
- Grade Buy
- Symbol (ALNY)
- Company Alnylam Pharmaceuticals, Inc.
- Price $270.02
- Changes Percentage (-1.42%)
- Change -$3.89
- Day Low $263.67
- Day High $272.92
- Year High $304.39
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/06/2025
- Fiscal Year End N/A
- Average Stock Price Target $253.00
- High Stock Price Target $400.00
- Low Stock Price Target $96.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.65
- Trailing P/E Ratio -57.65
- Forward P/E Ratio -57.65
- P/E Growth -57.65
- Net Income $-440,242,000
Income Statement
Quarterly
Annual
Latest News of ALNY
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Russian dissident Alex Navalny always knew he would die
Alexei Navalny, a vocal critic of Vladimir Putin, faced numerous challenges, including surviving a poisoning attempt and unjust imprisonments. Despite the risks, he remained dedicated to his fight aga...
By New York Post | 1 week ago -
Patriot by Alexei Navalny review - the man who dared to defy Putin
Alexei Navalny's memoir, "Patriot," recounts his remarkable life from childhood near Chornobyl to surviving a novichok attack and imprisonment in an Arctic penal colony....
By The Guardian | 1 week ago -
Russia's exiled opposition rocked by claims over hammer attack on Navalny ally
Allegations against Kremlin critic Leonid Nevzlin ordering an attack on Volkov have caused turmoil in the Russian opposition. The accusations, based on leaked messages, have led to infighting and disb...
By The Guardian | 1 month ago
